Sana Biotechnology Inc
$ 3.70
-3.14%
21 Apr - close price
- Market Cap 1,019,432,000 USD
- Current Price $ 3.70
- High / Low $ 3.93 / 3.62
- Stock P/E N/A
- Book Value 0.60
- EPS -0.96
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -1.19 %
- 52 Week High 6.55
- 52 Week Low 1.60
About
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
Analyst Target Price
$8.57
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-24 | 2025-11-06 | 2025-08-11 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-03 | 2023-05-08 |
| Reported EPS | -0.16 | -0.16 | -0.39 | -0.2 | -0.23 | -0.25 | -0.32 | -0.32 | -0.41 | 0.02 | -0.59 | -0.43 |
| Estimated EPS | -0.1444 | -0.18 | -0.2 | -0.2 | -0.2428 | -0.27 | -0.28 | -0.32 | -0.38 | -0.45 | -0.43 | -0.45 |
| Surprise | -0.0156 | 0.02 | -0.19 | 0 | 0.0128 | 0.02 | -0.04 | 0 | -0.03 | 0.47 | -0.16 | 0.02 |
| Surprise Percentage | -10.8033% | 11.1111% | -95% | 0% | 5.2718% | 7.4074% | -14.2857% | 0% | -7.8947% | 104.4444% | -37.2093% | 4.4444% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SANA
2026-04-21 07:10:34
Sana Biotechnology (SANA) is being re-evaluated after its collaboration with Mayo Clinic for SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes, which included an equity investment. Despite a recent 22.8% 30-day share price return and a significant 1-year total return, the stock remains down year-to-date. The company trades at a Price-to-Book (P/B) ratio of 6.5x, comparable to its peers but significantly higher than the broader US biotech industry average, indicating investors are assigning a higher value to its net assets despite no current revenue and a net loss of $244.166 million.
2026-04-20 21:10:34
Wedbush has increased its price target for Sana Biotechnology (SANA) to $7 from $6, reaffirming its Outperform rating. This decision follows Sana's collaboration with Mayo Clinic to develop type 1 diabetes candidate SC451, which includes an initial $25 million investment from Mayo Clinic for 7.5 million shares, extending Sana's cash runway into 2027. Sana Biotechnology focuses on engineered cell therapies for various conditions, including diabetes and oncology.
2026-04-19 22:12:00
This article highlights Sana Biotechnology, Inc. (SANA) as a top stock under $5 with significant upside potential. Wedbush recently raised its price target to $7 from $6 and reaffirmed an Outperform rating following Sana's collaboration with the Mayo Clinic for developing therapies for type 1 diabetes, which includes an investment of up to $50 million. Sana Biotechnology specializes in engineered cell therapies for various conditions, extending its cash runway into 2027.
2026-04-18 10:39:24
Intellectia AI recommends Sana Biotechnology Inc (SANA) as a "Buy" for long-term investors, citing a recent partnership with Mayo Clinic, positive analyst sentiment, and an extended cash runway into 2027. Technical analysis shows bullish momentum, though the company remains pre-revenue. Analysts like Wedbush and BofA have raised price targets, indicating confidence in SANA's future prospects.
2026-04-18 09:09:50
Sana Biotechnology, Inc. (NASDAQ:SANA) has received a "Moderate Buy" consensus rating from analysts, with an average one-year target price of $8.20. Despite missing quarterly EPS estimates, institutional and hedge fund ownership remains high, indicating investor interest. The company is a clinical-stage biopharmaceutical firm focused on developing engineered cell therapies for various diseases.
2026-04-17 11:10:34
Sana Biotechnology, Inc. (NASDAQ: SANA) is an early-stage biotech company focusing on cell engineering platforms for conditions like type 1 diabetes, autoimmune diseases, and oncology, presenting a potential 147% upside. Despite current negative valuation metrics typical of pre-revenue firms, its innovative pipeline and strategic collaborations, including with Beam Therapeutics and Mayo Clinic, are supported by strong analyst sentiment. The stock's future performance hinges on clinical trial advancements and partnership growth, positioning it as a high-risk, high-reward opportunity within the evolving biotech sector.
